about
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancerCancer classification using the Immunoscore: a worldwide task forceTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursSMAD2, SMAD3 and SMAD4 mutations in colorectal cancerDetection of circulating tumor DNA in early- and late-stage human malignanciesGermline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.Linking data from hospital and cancer registry databases: should this be standard practice?Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer.Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).BioGrid Australia facilitates collaborative medical and bioinformatics research across hospitals and medical research institutes by linking data from diverse disease and data types.Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces.Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data.Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal CancerPHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis.Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerSelective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX sTolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution.The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.Blood-based protein biomarker panel for the detection of colorectal cancerRefinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion.Cytosine methylation profiling of cancer cell lines.Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutationOptimizing the approach to patients with potentially resectable liver metastases from colorectal cancer.DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer.Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis.Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice?Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.Surgical oncology issues in locally advanced rectal cancer.Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.Outcomes in the surgical treatment of low rectal cancer: does neoadjuvant treatment equalize results?Serious hepatic complications of selective internal radiation therapy with yttrium-90 microsphere radioembolization for unresectable liver tumors.Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care.Comparing oncological outcomes of laparoscopic versus open surgery for colon cancer: Analysis of a large prospective clinical database.Guesstimates are not good enough for determining what is happening in routine care.
P50
Q21144952-8CCA71D7-DAD7-479D-96EA-A5F169629A40Q21245495-50A28DFC-675F-4329-9B8D-862FFE00A59EQ27026489-E03B7BCB-4B8E-4CDA-9862-A5389997709BQ28278952-DA4A3084-995A-4A67-9E5E-27410B5FBDF6Q29615778-52CF971A-C382-4F66-A375-108EEC0E92D6Q30579114-41E04C3B-1502-41FA-B283-12509E4D4E17Q33449871-4224E3F8-FDE2-487A-8E7E-DCBC001E0F88Q33555345-1BA76B84-2F04-4964-BA7D-B7F96663B8F5Q33706508-BFFC56EA-E59E-4345-8342-C8F81B0AAF89Q33813216-323478BC-4BA3-4569-A01F-FA50DEB86711Q33817278-FBDAD9CA-9E93-457F-AE09-63A3238DFF4CQ33888509-993AB27B-52EE-4195-840E-2146825B94A6Q34007614-5E7221EE-12BF-4981-91EA-8596360622C4Q34062558-A45BACDC-213D-4F68-815B-D4A1C44425B6Q34184024-1C1DEE80-ACE0-4097-A8EB-8C1BC0202228Q34628085-9C5FF17D-4C89-46D5-AA7E-52E336839625Q34894115-34C3F575-8D65-4FF6-B45C-950ED0614D64Q34946877-3BDDDC6F-4829-4934-BFA0-66005524795FQ35160866-B8F35B66-4ECA-4477-AC10-190E395517B3Q35187723-B24A8DB4-B6B2-4E50-952D-5FADF63C2796Q35202822-A686D13C-6CF7-4555-BE30-F9E2F7D8A20FQ35688605-39993041-C176-418B-9993-242D54B3A649Q36531671-9E91ACDA-89B1-4F27-A0C8-D0B19A5E6C75Q36534546-FD3F91B0-0DEC-4874-9B4F-AE0C21BB2EC6Q36551145-DAEDE70E-F2B5-4CAB-9CCC-97BF80347B61Q36968386-F78F3EAA-11FA-46E6-BAA1-428B31379E9BQ37020817-BADF56E0-30BD-4999-8E2B-29773CABF9ECQ37093977-A70A44A5-52D5-4F12-8456-370A2A179811Q37209240-072B993B-FA88-46D2-8F33-ABFDFE69EE31Q37476887-3C78A281-BAC6-4DD8-B018-81F1274015C1Q37477083-F1BA29A9-3408-40CC-9053-F4A81D3BB204Q37980472-D1A7CE9B-DA3A-46AA-9397-A86070925F26Q38023976-0D07A1DE-1F07-4B58-B7D2-B4FE26844147Q38169587-C3959AC4-5BAA-49A8-AB36-711D14382F1CQ38236794-716CF1DB-42A1-468C-96B0-D5128CC48934Q38241076-FC267234-5D4E-4582-ACAF-B4B8575F460CQ38241395-A99877E4-0CF8-4934-A388-2A89CA393131Q40354587-7CF2B7DE-C39C-4B15-B2EE-FDBD3B2EF2CDQ41355519-8F756779-7498-4274-B842-2742B819AE20Q42552253-11692762-C345-43E9-AD06-F2649E448F2C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter Gibbs
@ast
Peter Gibbs
@en
Peter Gibbs
@es
Peter Gibbs
@nl
Peter Gibbs
@sl
type
label
Peter Gibbs
@ast
Peter Gibbs
@en
Peter Gibbs
@es
Peter Gibbs
@nl
Peter Gibbs
@sl
prefLabel
Peter Gibbs
@ast
Peter Gibbs
@en
Peter Gibbs
@es
Peter Gibbs
@nl
Peter Gibbs
@sl
P106
P21
P31
P496
0000-0003-1423-4484